News 20 oct 2023 Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine Lonza and US clinical-stage vaccine innovation company Vaxcyte have announced an expansion in their partnership to establish a global commercial ...
Novità 30 jan 2018 La Svizzera resta il leader mondiale dell’innovazione La Svizzera continua a registrare livelli eccezionali in fatto di innovazione. È giunto di nuovo il momento di scegliere il paese più innovativo ...
Actualités 13 sep 2023 HAYA Therapeutics triomphe lors de la 13e édition du TOP 100 Swiss Startup Award La scène florissante des start-ups en Suisse occidentale a connu une nouvelle année remarquable d'innovation et de croissance, Haya Therapeutics ...
Drittpartei Event Investitionen in asiatischen Ländern – Rechtliche und politische Rahmenbedingungen Bern Schweiz
News 11 oct 2023 Orio Therapeutics partners with Australia’s largest University to transform regenerative medicine In a stride towards redefining regenerative medicine, Monash University collaborates with Valais-based Orio Therapeutics to innovate in the realm...
News 11 oct 2023 Lonza further extends its ADC manufacturing capabilities in Visp Lonza amplifies ADC production via a robust extension in bioconjugation capacity at its Ibex Dedicate Biopark in Visp, which set to generate 180 ...
Communiqués de Presse 30 jan 2024 Stagnation des exportations: les PME suisses revoient leurs attentes à la baisse Les PME suisses ne tablent plus que sur une croissance minime de leurs ventes à l’étranger, selon la dernière enquête de Switzerland Global Enter...
News 06 nov 2023 Investors stump up 3.7 million Swiss francs in Onena Medicines Onena Medicines has secured investment of 3.7 million Swiss francs. The portfolio company of the biotech start-up incubator BaseLaunch will there...
News 15 aoû 2022 BioFi AG newly settles in Basel BioFi has set up its headquarters in Basel. The company has emerged from Crowley Davis Research, which was established in the US state of Idaho i...
News 03 nov 2023 EPFL and Novochizol to collaborate on designing more efficient immunotherapies A groundbreaking collaboration between EPFL's Laboratory of Biomaterials for Immunoengineering and Novochizol aims to revolutionize cancer treatm...
News 05 sep 2023 Mabylon further develops active substance to treat peanut allergy with Pfizer Biotech company Mabylon has entered into an agreement with the biotech promoter Pfizer Ignite. Mabylon plans to use this to expedite the developm...
News 10 oct 2023 HES-SO Valais-Wallis and Debiopharm partner up to battle cancer HES-SO Valais-Wallis and Debiopharm have entered a partnership to advance targeted cancer therapy research with novel antibody conjugates.
Industry Report 31 jan 2022 The Russian Market of Laboratory Diagnostic Services In Russia there are various health organisations providing medical laboratory diagnostics; they comprise public medical institutions, such as sci...
Third Party Event Colombia and its regions: business and investment opportunities in a transformed emerging market Genève Switzerland
Actualités 24 aoû 2023 Le pionnier de la nanomédecine Nanobacterie se distingue par ses brevets Forte des réalisations de sa société mère Nanobacterie, la société valaisanne AlphaOnco Swiss est à l'avant-garde des traitements anticancéreux i...
Actualités 11 mai 2021 Le spécialiste vaudois des traitements ophtalmiques Oculis lève $ 57 millions Oculis, société biopharmaceutique spécialisée dans le développement de traitements ophtalmiques innovants, a annoncé la clôture d’un tour de fina...
Actualités 30 avr 2021 ADC Therapeutics reçoit l’approbation du FDA pour son traitement du lymphome cancéreux ZYNLONTA La société de biotechnologie oncologique ADC Therapeutics a reçu la première approbation du FDA pour ZYNLONTA, son traitement pour les patients a...
News 06 sep 2023 ten23 health boosts sterile production capacity and introduces new quality control services Renowned for its expertise in sterile drug product manufacturing, Valais-based ten23 health is taking significant steps to expand its services an...